Clinical Trials Sponsored by Ascentage Pharma Group Inc.

Total 81 results

Ascentage Pharma Group Inc.

Recruiting

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

CLL/SLL

China
Ascentage Pharma Group Inc.

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

CLL/SLL

Russian Federation
Ascentage Pharma Group Inc.

Recruiting

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | B Cell Lymphoma | Mesothelioma | Non Hodgkin Lymphoma | Ovarian Clear Cell Carcinoma | Epithelioid Sarcoma | Castrate Resistant Prostate Cancer

United States
Ascentage Pharma Group Inc.

Recruiting

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Ascentage Pharma Group Inc.

Recruiting

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Breast Cancer | Solid Tumor, Adult

United States
Ascentage Pharma Group Inc.

Recruiting

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Advanced Pancreatic Cancer

China
Ascentage Pharma Group Inc.

Recruiting

A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

Hepatitis B | HBV | Chronic Hep B

China
Ascentage Pharma Group Inc.

Recruiting

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Advanced Solid Tumor

China
Ascentage Pharma Group Inc.

Recruiting

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

CLL/SLL

United States, Australia
Ascentage Pharma Group Inc.

Not yet recruiting

A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML (POLARIS-2)

Chronic Myeloid Leukemia | CML | CML, Chronic Phase

United States
Ascentage Pharma Group Inc.

Recruiting

A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

Anemia

China
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

AML, Adult

Australia, United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Amyloidosis

United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Ascentage Pharma Group Inc.

Recruiting

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Advanced Solid Tumors or Hematologic Malignancies

United States
Ascentage Pharma Group Inc.

Completed

APG-115 in Patients With Advanced Solid Tumors or Lymphomas (APG-115)

Patients With Advanced Solid Tumor or Lymphoma

United States
Ascentage Pharma Group Inc.

Terminated

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Australia
Ascentage Pharma Group Inc.

Not yet recruiting

A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Ascentage Pharma Group Inc.

Recruiting

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

NHL, Adult

China
Ascentage Pharma Group Inc.

Recruiting

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

China
Ascentage Pharma Group Inc.

Recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL

T-Prolymphocytic Leukemia

United States
Ascentage Pharma Group Inc.

Recruiting

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic Syndrome

United States
Ascentage Pharma Group Inc.

Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Myeloid Leukemia | Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Leukemia, Myeloid, Chronic | B Cell Precursor Type Acute Leukemia

United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Hematologic Malignancies

United States, Australia
Ascentage Pharma Group Inc.

Completed

The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

Pharmacokinetics

China
Ascentage Pharma Group Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

Chronic Myeloid Leukemia, Chronic Phase

China
Ascentage Pharma Group Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Chronic Myeloid Leukemia - Accelerated Phase

China
Ascentage Pharma Group Inc.

Withdrawn

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Myelofibrosis

United States
Ascentage Pharma Group Inc.

Completed

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Small Cell Lung Cancer | Solid Tumor

United States
Ascentage Pharma Group Inc.
Tanner Pharma Group

Available

Named Patient Program for Olverembatinib (HQP1351)
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Ph+ ALL

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Completed

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Completed

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Chronic Myeloid Leukemia (CML)

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Recruiting

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Solid Tumor, Adult | Gastrointestinal Stromal Tumor (GIST)

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Completed

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia, Chronic Phase

China
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.

Not yet recruiting

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Advanced Chronic Myeloid Leukemia | Philadelphia Chromosome-Positive Acute Myeloid Leukemia

United States
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

EGFR Positive Non-small Cell Lung Cancer

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Solid Tumor | Neuroblastoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Advanced Solid Tumor | Liposarcoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-2449 in Patients With Advanced Solid Tumors

Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Malignant Pleural Mesothelioma | Advanced Solid Cancer

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Terminated

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Small Cell Lung Cancer and Other Solid Tumors

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

SLE

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

China
University of Michigan Rogel Cancer Center
Ascentage Pharma Group Inc.

Active, not recruiting

APG-115 in Salivary Gland Cancer Trial

Salivary Gland Cancer | Malignant Salivary Gland Cancer

United States

Clinical Trials Sponsored by Ascentage Pharma Group Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations